# US 2026/0085129 A1 · Cd163 binding protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085129 A1
- Document ID: US20260085129A1
- Status: Published application
- Kind: A1
- Application number: 19/119,956
- Filed: 2023-10-11
- Published: 2026-03-26
- Earliest claimed: 2022-10-11
- Assignees: Eco Animal Health Limited
- Applicants: Eco Animal Health Ltd.
- Inventors: Christine TAIT-BURKARD; Charles Edward OWEN; Hafid Abdelaali BENCHAOUI
- Web page: https://patentgrep.com/patent/US20260085129A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61P 31/14: for RNA viruses
- A61K 2039/505: {comprising antibodies}
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/62: comprising only variable region components
- C07K 2317/626: Diabody or triabody
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides an antibody which binds to porcine CD163, wherein said antibody binds to the membrane-bound form of porcine CD163 on cells and does not bind significantly to the soluble form of porcine CD163. The present disclosure also provides a combination of said antibody with one or more further anti-porcine CD163 antibodies or binding proteins. Preferred combinations are those in which each antibody or binding protein binds to a different epitope in porcine CD163, and wherein said combination of anti-porcine CD163 antibodies or binding proteins are provided in a single construct. Nucleic acid molecules, expression vectors and compositions are also provided.

## Claims

### Claim 1

An antibody which binds to porcine CD163, wherein said antibody:
(i) binds to the membrane-bound form of porcine CD163 on cells; and
(ii) does not bind significantly to the soluble form of porcine CD163.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein said antibody has the ability to bind to the SRCR5 domain of porcine CD163.

### Claim 3 (depends on 1)

The antibody of claim 1, or a binding protein, comprising at least one antigen binding domain which binds to porcine CD163, said antigen binding domain comprising a heavy chain variable region which comprises three complementarity determining regions (CDRs), wherein said heavy chain variable region comprises:
(i) a variable heavy (VH) CDR1 that comprises the amino acid sequence of GRTFSSYA (SEQ ID NO:2), or a sequence substantially homologous thereto, wherein said substantially homologous sequence is a sequence containing 1, 2 or 3 amino acid substitutions compared to the given CDR sequence,
(ii) a variable heavy (VH) CDR2 that comprises the amino acid sequence of IGWTGGTT (SEQ ID NO:3), or a sequence substantially homologous thereto, wherein said substantially homologous sequence is a sequence containing 1, 2 or 3 amino acid substitutions compared to the given CDR sequence, and
(iii) a variable heavy (VH) CDR3 that comprises the amino acid sequence of AADQAGWRTAGVRNTYEYDY (SEQ ID NO:4), or a sequence substantially homologous thereto, wherein said substantially homologous sequence is a sequence containing 1, 2, 3 or 4 amino acid substitutions compared to the given CDR sequence.

### Claim 4 (depends on 3)

The antibody or binding protein of claim 3, wherein said heavy chain variable region comprises:
(i) a variable heavy (VH) CDR1 that comprises the amino acid sequence of GRTFSSYA (SEQ ID NO:2),
(ii) a variable heavy (VH) CDR2 that comprises the amino acid sequence of IGWTGGTT (SEQ ID NO:3), and
(iii) a variable heavy (VH) CDR3 that comprises the amino acid sequence of AADQAGWRTAGVRNTYEYDY (SEQ ID NO:4).

### Claim 5 (depends on 1)

The antibody of claim 1, comprising a VH domain that comprises the amino acid sequence of SEQ ID NO: 1 or a sequence having at least 70%, 75% or 80% sequence identity thereto.

### Claim 6 (depends on 3)

An antibody that binds to the same epitope of porcine CD163 as the antibody of claim 3.

### Claim 7 (depends on 1)

A combination of the antibody of claim 1, with one or more further anti-porcine CD163 antibodies or binding proteins, preferably with one or two further anti-porcine CD163 antibodies or binding proteins.

### Claim 8 (depends on 7)

The combination of claim 7, wherein each antibody or binding protein binds to a different epitope of porcine CD163.

### Claim 9 (depends on 7)

The combination of claim 7, wherein a said further anti-porcine CD163 antibody or binding protein comprises at least one antigen binding domain which binds to porcine CD163, said antigen binding domain comprising a heavy chain variable region which comprises three complementarity determining regions (CDRs), wherein said heavy chain variable region comprises:
(i) a variable heavy (VH) CDR1 that comprises the amino acid sequence of RYVMG (SEQ ID NO:10), or a sequence substantially homologous thereto, wherein said substantially homologous sequence is a sequence containing 1 or 2 amino acid substitutions compared to the given CDR sequence,
(ii) a variable heavy (VH) CDR2 that comprises the amino acid sequence of AISWSGRAPYADSVKG (SEQ ID NO:11), or a sequence substantially homologous thereto, wherein said substantially homologous sequence is a sequence containing 1, 2, 3 or 4 amino acid substitutions compared to the given CDR sequence, and
(iii) a variable heavy (VH) CDR3 that comprises the amino acid sequence of GEGAIKWTTLDAYDY (SEQ ID NO:12), or a sequence substantially homologous thereto, wherein said substantially homologous sequence is a sequence containing 1, 2, 3 or 4 amino acid substitutions compared to the given CDR sequence; and/or
wherein a said further anti-porcine CD163 antibody or binding protein comprises at least one antigen binding domain which binds to porcine CD163, said antigen binding domain comprising a heavy chain variable region which comprises three complementarity determining regions (CDRs), wherein said heavy chain variable region comprises:
(i) a variable heavy (VH) CDR1 that comprises the amino acid sequence of DYTIG (SEQ ID NO:18), or a sequence substantially homologous thereto, wherein said substantially homologous sequence is a sequence containing 1 or 2 amino acid substitutions compared to the given CDR sequence,
(ii) a variable heavy (VH) CDR2 that comprises the amino acid sequence of CINSITSNTYYADSVKG (SEQ ID NO:19), or a sequence substantially homologous thereto, wherein said substantially homologous sequence is a sequence containing 1, 2, 3 or 4 amino acid substitutions compared to the given CDR sequence, and
(iii) a variable heavy (VH) CDR3 that comprises the amino acid sequence of DSGLFSGSSCLKYRAMRFGS (SEQ ID NO:20), or a sequence substantially homologous thereto, wherein said substantially homologous sequence is a sequence containing 1, 2, 3 or 4 amino acid substitutions compared to the given CDR sequence.

### Claim 10 (depends on 7)

The combination of claim 7, wherein said combination of anti-porcine CD163 antibodies or binding proteins are provided in a single construct, preferably wherein said combination contains two or three anti-porcine CD163 antibodies or binding proteins.

### Claim 11 (depends on 7)

The combination of claim 7, wherein one or more, or all, of said antibodies is a single domain antibody.

### Claim 12 (depends on 1)

The antibody of claim 1, further comprising an entity that can extend the half-life of said antibody, binding protein or combination, preferably albumin or an IgG Fc region.

### Claim 13 (depends on 1)

One or more nucleic acid molecules comprising nucleotide sequences that encode the antibody of claim 1, or one or more expression vectors comprising such nucleic acid molecules, or one or more host cells comprising said expression vectors or said nucleic acid molecules or expressing the antibody of claim 1.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 13)

A method of producing an antibody, said method comprising the steps of (i) culturing a host cell of claim 13, under conditions suitable for the expression of the encoded antibody; and optionally (ii) isolating or obtaining the antibody from the host cell or from the culture medium/supernatant.

### Claim 17 (depends on 1)

A composition comprising an antibody of claim 1, one or more nucleic acid molecules encoding said antibody, one or more expression vectors comprising said nucleic acid molecules, or one or more host cells comprising said expression vectors, or said nucleic acid molecules, or expressing the antibody of claim 1.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 7)

A method of treatment or prevention of PRRSV infection in a subject, which method comprises administering to a subject in need thereof a therapeutically effective amount of the combination of claim 7, one or more nucleic acid molecules encoding said combination, one or more expression vectors comprising said nucleic acid molecules, or one or more host cells comprising said expression vectors, or said nucleic acid molecules, or expressing the combination of claim 7.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The method of claim 20, wherein said subject is a pig.

### Claim 23 (depends on 1)

A method of treatment or prevention of PRRSV infection in a subject, which method comprises administering to a subject in need thereof a therapeutically effective amount of the antibody of claim 1, one or more nucleic acid molecules encoding said antibody, one or more expression vectors encoding said nucleic acid molecules, or one or more host cells comprising said expression vectors, or said nucleic acid molecules, or expressing the antibody of claim 1.

### Claim 24 (depends on 23)

The method of claim 23, wherein said subject is a pig.

### Claim 25 (depends on 1)

The antibody of claim 1, wherein said antibody is a single domain antibody.